サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1701667

口腔内崩壊錠（ODT）の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Orally Disintegrating Tablet Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 179 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
口腔内崩壊錠（ODT）の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月08日
発行: Persistence Market Research
ページ情報: 英文 179 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な調査結果

  • 口腔内崩壊錠（ODT）の市場規模：250億8,210万米ドル（2025年）
  • 予測される市場金額：481億8,680万米ドル（2032年）
  • 世界市場の成長率：8.5%（2025年～2032年のCAGR）

口腔内崩壊錠（ODT）市場 - レポート範囲

口腔内崩壊錠（ODT）市場は、水を必要とせずに口腔内で速やかに溶解または崩壊する薬剤で構成されます。これらの錠剤は、投与が容易で、患者コンプライアンスが向上し、小児や高齢者に適しているため、さまざまな治療領域で広く使用されています。革新的なドラッグデリバリーシステムに対する需要の高まりは、慢性疾患や神経疾患の有病率の増加もあり、ODTの採用を加速させています。製薬企業は先進の製剤技術に投資し、患者のアンメットニーズをターゲットにしてポートフォリオを拡大し、市場シェアを拡大しています。

市場成長の促進要因

世界のODT市場は、複数の有利な要因により着実な成長を示しています。てんかん、パーキンソン病、統合失調症などの神経・精神疾患の罹患率の増加は、ODTが嚥下の困難な患者にとって便利な剤形であることから、需要に大きく寄与しています。さらに、小児と高齢者という、従来の錠剤が課題となる2つの重要な層の拡大が、ODTの採用をさらに後押ししています。さらに、鎮痛やアレルギーなどの治療領域で即効性のある製剤への需要が高まっていることも、製薬企業が既存薬のODT版を開発する後押しとなっています。味覚マスキングや急速崩壊の技術的進歩も、より口当たりが良く効果的なODTの開発を促進し、患者の服薬アドヒアランスと治療成績を向上させています。

市場抑制要因

ODT市場は力強い成長が見込まれる一方、複数の制限に直面しています。主な課題の1つは、従来の錠剤に比べてODTの製造が複雑でコストがかかることです。これらの製剤は、凍結乾燥や直接打錠などの特殊な設備や技術を必要とすることが多く、資本集約的なものとなる可能性があります。さらに、すべての医薬品がODT製剤に適しているわけではなく、特に必要投与量の多い医薬品や、効果的なマスキングが困難な不快な味を持つ医薬品には適していません。特に湿気に敏感な化合物では、規制上のハードルや安定性への懸念が製品の承認や市場投入までの時間を遅らせ、成長を抑制する可能性もあります。

市場機会

ODT市場には、成長とイノベーションの機会が数多くあります。患者中心の薬剤設計への注目の高まりと自己投与薬の人気の高まりは、市場拡大に向けた強力な基盤となっています。製薬企業は、製品の差別化と特許期間の延長を図るため、ODTに適した新規のAPIや多剤混合薬を模索しています。アジア太平洋、ラテンアメリカ、中東・アフリカの新興市場における医療アクセスの拡大には、特にオンラインや小売薬局のチャネルを通じた未開発の可能性があります。さらに、医薬品開発企業と製造受託機関（CMO）の戦略的提携により、コスト効率の高い生産が可能になり、新しいODT製品の迅速な商業化につながります。

当レポートでは、世界の口腔内崩壊錠（ODT）市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 規制情勢
  • 製品採用分析
  • バリューチェーン分析
  • 主な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の口腔内崩壊錠（ODT）市場の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界の口腔内崩壊錠（ODT）市場の見通し：薬剤クラス
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：薬剤クラス別（2019年～2024年）
    • 現在の市場規模の分析と予測：薬剤クラス別（2025年～2032年）
    • 市場の魅力分析：薬剤クラス
  • 世界の口腔内崩壊錠（ODT）市場の見通し：適応症
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：適応症別（2019年～2024年）
    • 現在の市場規模の分析と予測：適応症別（2025年～2032年）
    • 市場の魅力分析：適応症
  • 世界の口腔内崩壊錠（ODT）市場の見通し：流通チャネル
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：流通チャネル別（2019年～2024年）
    • 現在の市場規模の分析と予測：流通チャネル別（2025年～2032年）
    • 市場の魅力分析：流通チャネル

第5章 世界の口腔内崩壊錠（ODT）市場の見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の口腔内崩壊錠（ODT）市場の見通し

第7章 欧州の口腔内崩壊錠（ODT）市場の見通し

第8章 東アジアの口腔内崩壊錠（ODT）市場の見通し

第9章 南アジア・オセアニアの口腔内崩壊錠（ODT）市場の見通し

第10章 ラテンアメリカの口腔内崩壊錠（ODT）市場の見通し

第11章 中東・アフリカの口腔内崩壊錠（ODT）市場の見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • AstraZeneca
    • Mylan NV
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Bausch Health
    • GlaxoSmithKline plc.
    • Sun Pharmaceutical Industries Ltd.
    • Bayer AG
    • Eli Lily and Company
    • Dr. Reddy's Laboratories Ltd.
    • Takeda Pharmaceutical Company Limited
    • Catalent Pharma Solutions
    • Neos Therapeutics
    • Eisai Co.
    • Zydus Lifesciences
    • Aurobindo Pharma
    • Torrent Pharmaceuticals

第13章 付録

目次
Product Code: PMRREP14572

Persistence Market Research has recently released a comprehensive report on the global Orally Disintegrating Tablet (ODT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Orally Disintegrating Tablet Market Size (2025E): US$ 25,082.1 Mn
  • Projected Market Value (2032F): US$ 48,186.8 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.5%

Orally Disintegrating Tablet Market - Report Scope:

The Orally Disintegrating Tablet (ODT) market comprises pharmaceutical formulations that dissolve or disintegrate rapidly in the mouth without the need for water. These tablets are widely used across various therapeutic areas due to their ease of administration, improved patient compliance, and suitability for pediatric and geriatric populations. Rising demand for innovative drug delivery systems, coupled with growing prevalence of chronic and neurological disorders, is accelerating the adoption of ODTs. Pharmaceutical companies are investing in advanced formulation technologies and targeting unmet patient needs to expand their portfolios and capture greater market share.

Market Growth Drivers:

The global ODT market is experiencing steady growth due to several favorable factors. The increasing incidence of neurological and psychiatric conditions, such as epilepsy, Parkinson's disease, and schizophrenia, is contributing significantly to demand, as ODTs offer a more convenient dosage form for patients who have difficulty swallowing. Moreover, the growing pediatric and geriatric population-two key demographics for whom traditional tablets pose challenges-further drives the adoption of ODTs. Additionally, the rise in demand for faster-acting formulations in therapeutic areas like pain relief and allergies has encouraged pharmaceutical firms to develop ODT versions of existing drugs. Technological advancements in taste-masking and rapid disintegration are also facilitating the development of more palatable and effective ODTs, enhancing patient adherence and therapeutic outcomes.

Market Restraints:

Despite strong growth prospects, the ODT market faces several limitations. One of the key challenges is the complexity and cost of manufacturing ODTs compared to conventional tablets. These formulations often require specialized equipment and technologies such as lyophilization or direct compression, which can be capital-intensive. Moreover, not all drugs are suitable for ODT formulations, especially those with high dosage requirements or unpleasant taste profiles that are difficult to mask effectively. Regulatory hurdles and stability concerns, particularly with moisture-sensitive compounds, can also delay product approvals and time-to-market, thereby restraining growth.

Market Opportunities:

The ODT market presents numerous opportunities for growth and innovation. Increasing focus on patient-centric drug design and the growing popularity of self-administered medication provide a strong foundation for market expansion. Pharmaceutical companies are exploring novel APIs and fixed-dose combinations suitable for ODTs to differentiate their product offerings and extend patent life. Expanding access to healthcare in emerging markets across Asia-Pacific, Latin America, and the Middle East and Africa presents untapped potential, particularly through online and retail pharmacy channels. Furthermore, strategic collaborations between drug developers and contract manufacturing organizations (CMOs) can facilitate cost-effective production and faster commercialization of new ODT products.

Key Questions Answered in the Report:

  • What are the primary factors driving the global ODT market's growth?
  • Which regions and therapeutic segments are witnessing the highest demand for ODTs?
  • How are innovations in formulation technology influencing market dynamics?
  • Who are the key players in the ODT market, and what strategies are they adopting to remain competitive?
  • What are the emerging trends and future projections for the global ODT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global ODT market, such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., and Pfizer Inc., are focusing on formulation innovation, lifecycle management of blockbuster drugs, and expanding their presence in high-growth regions. These players are also investing in taste-masking technologies, disintegration enhancers, and fast-melt systems to improve patient experience and treatment outcomes. Strategic partnerships, mergers and acquisitions, and co-development agreements are common approaches to gain competitive advantage. In addition, the emergence of digital pharmacies and evolving consumer preferences toward convenience-based healthcare solutions are shaping new business models in the ODT landscape.

Companies Covered in This Report:

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca
  • Mylan N.V.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bausch Health
  • GlaxoSmithKline plc.
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Eli Lilly and Company

Orally Disintegrating Tablet Market Segmentation:

By Drug Class:

  • Anti-Psychotics
  • Anti-Epileptics
  • CNS Stimulants
  • Anxiolytics
  • Anti-Parkinsonian Drugs
  • Anti-Hypertensives
  • NSAIDs
  • Anti-Allergy Drugs
  • Proton Pump Inhibitors
  • Others

By Disease Indication:

  • CNS Diseases
  • GI Diseases
  • CVS Disorders
  • Allergy
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Orally Disintegrating Tablet Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Orally Disintegrating Tablet Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Orally Disintegrating Tablet Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
      • 4.3.3.1. Anti-Psychotics
      • 4.3.3.2. Anti-Epileptics
      • 4.3.3.3. CNS Stimulants
      • 4.3.3.4. Anxiolytics
      • 4.3.3.5. Anti-Parkinsonian Drugs
      • 4.3.3.6. Anti-Hypertensives
      • 4.3.3.7. NSAIDS
      • 4.3.3.8. Anti-Allergy Drugs
      • 4.3.3.9. Proton Pump Inhibitors
      • 4.3.3.10. Others
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Orally Disintegrating Tablet Market Outlook: Disease Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
      • 4.4.3.1. CNS Diseases
      • 4.4.3.2. GI Diseases
      • 4.4.3.3. CVS Disorders
      • 4.4.3.4. Allergy
      • 4.4.3.5. Others
    • 4.4.4. Market Attractiveness Analysis: Disease Indication
  • 4.5. Global Orally Disintegrating Tablet Market Outlook: Distribution Channel
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
      • 4.5.3.1. Hospital Pharmacies
      • 4.5.3.2. Retail Pharmacies
      • 4.5.3.3. Drug Stores
      • 4.5.3.4. Online Pharmacies
    • 4.5.4. Market Attractiveness Analysis: Distribution Channel

5. Global Orally Disintegrating Tablet Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Orally Disintegrating Tablet Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Disease Indication
    • 6.2.4. By Distribution Channel
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 6.4.1. Anti-Psychotics
    • 6.4.2. Anti-Epileptics
    • 6.4.3. CNS Stimulants
    • 6.4.4. Anxiolytics
    • 6.4.5. Anti-Parkinsonian Drugs
    • 6.4.6. Anti-Hypertensives
    • 6.4.7. NSAIDS
    • 6.4.8. Anti-Allergy Drugs
    • 6.4.9. Proton Pump Inhibitors
    • 6.4.10. Others
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 6.5.1. CNS Diseases
    • 6.5.2. GI Diseases
    • 6.5.3. CVS Disorders
    • 6.5.4. Allergy
    • 6.5.5. Others
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies
    • 6.6.3. Drug Stores
    • 6.6.4. Online Pharmacies
  • 6.7. Market Attractiveness Analysis

7. Europe Orally Disintegrating Tablet Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Disease Indication
    • 7.2.4. By Distribution Channel
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 7.4.1. Anti-Psychotics
    • 7.4.2. Anti-Epileptics
    • 7.4.3. CNS Stimulants
    • 7.4.4. Anxiolytics
    • 7.4.5. Anti-Parkinsonian Drugs
    • 7.4.6. Anti-Hypertensives
    • 7.4.7. NSAIDS
    • 7.4.8. Anti-Allergy Drugs
    • 7.4.9. Proton Pump Inhibitors
    • 7.4.10. Others
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 7.5.1. CNS Diseases
    • 7.5.2. GI Diseases
    • 7.5.3. CVS Disorders
    • 7.5.4. Allergy
    • 7.5.5. Others
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies
    • 7.6.3. Drug Stores
    • 7.6.4. Online Pharmacies
  • 7.7. Market Attractiveness Analysis

8. East Asia Orally Disintegrating Tablet Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Disease Indication
    • 8.2.4. By Distribution Channel
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 8.4.1. Anti-Psychotics
    • 8.4.2. Anti-Epileptics
    • 8.4.3. CNS Stimulants
    • 8.4.4. Anxiolytics
    • 8.4.5. Anti-Parkinsonian Drugs
    • 8.4.6. Anti-Hypertensives
    • 8.4.7. NSAIDS
    • 8.4.8. Anti-Allergy Drugs
    • 8.4.9. Proton Pump Inhibitors
    • 8.4.10. Others
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 8.5.1. CNS Diseases
    • 8.5.2. GI Diseases
    • 8.5.3. CVS Disorders
    • 8.5.4. Allergy
    • 8.5.5. Others
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies
    • 8.6.3. Drug Stores
    • 8.6.4. Online Pharmacies
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Orally Disintegrating Tablet Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Disease Indication
    • 9.2.4. By Distribution Channel
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 9.4.1. Anti-Psychotics
    • 9.4.2. Anti-Epileptics
    • 9.4.3. CNS Stimulants
    • 9.4.4. Anxiolytics
    • 9.4.5. Anti-Parkinsonian Drugs
    • 9.4.6. Anti-Hypertensives
    • 9.4.7. NSAIDS
    • 9.4.8. Anti-Allergy Drugs
    • 9.4.9. Proton Pump Inhibitors
    • 9.4.10. Others
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 9.5.1. CNS Diseases
    • 9.5.2. GI Diseases
    • 9.5.3. CVS Disorders
    • 9.5.4. Allergy
    • 9.5.5. Others
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies
    • 9.6.3. Drug Stores
    • 9.6.4. Online Pharmacies
  • 9.7. Market Attractiveness Analysis

10. Latin America Orally Disintegrating Tablet Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Disease Indication
    • 10.2.4. By Distribution Channel
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 10.4.1. Anti-Psychotics
    • 10.4.2. Anti-Epileptics
    • 10.4.3. CNS Stimulants
    • 10.4.4. Anxiolytics
    • 10.4.5. Anti-Parkinsonian Drugs
    • 10.4.6. Anti-Hypertensives
    • 10.4.7. NSAIDS
    • 10.4.8. Anti-Allergy Drugs
    • 10.4.9. Proton Pump Inhibitors
    • 10.4.10. Others
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 10.5.1. CNS Diseases
    • 10.5.2. GI Diseases
    • 10.5.3. CVS Disorders
    • 10.5.4. Allergy
    • 10.5.5. Others
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies
    • 10.6.3. Drug Stores
    • 10.6.4. Online Pharmacies
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Orally Disintegrating Tablet Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Disease Indication
    • 11.2.4. By Distribution Channel
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 11.4.1. Anti-Psychotics
    • 11.4.2. Anti-Epileptics
    • 11.4.3. CNS Stimulants
    • 11.4.4. Anxiolytics
    • 11.4.5. Anti-Parkinsonian Drugs
    • 11.4.6. Anti-Hypertensives
    • 11.4.7. NSAIDS
    • 11.4.8. Anti-Allergy Drugs
    • 11.4.9. Proton Pump Inhibitors
    • 11.4.10. Others
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 11.5.1. CNS Diseases
    • 11.5.2. GI Diseases
    • 11.5.3. CVS Disorders
    • 11.5.4. Allergy
    • 11.5.5. Others
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Retail Pharmacies
    • 11.6.3. Drug Stores
    • 11.6.4. Online Pharmacies
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Teva Pharmaceutical Industries Ltd.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Novartis AG
    • 12.3.3. AstraZeneca
    • 12.3.4. Mylan N.V.
    • 12.3.5. Pfizer Inc.
    • 12.3.6. Johnson & Johnson Services, Inc.
    • 12.3.7. F. Hoffmann-La Roche Ltd.
    • 12.3.8. Merck & Co., Inc.
    • 12.3.9. Bausch Health
    • 12.3.10. GlaxoSmithKline plc.
    • 12.3.11. Sun Pharmaceutical Industries Ltd.
    • 12.3.12. Bayer AG
    • 12.3.13. Eli Lily and Company
    • 12.3.14. Dr. Reddy's Laboratories Ltd.
    • 12.3.15. Takeda Pharmaceutical Company Limited
    • 12.3.16. Catalent Pharma Solutions
    • 12.3.17. Neos Therapeutics
    • 12.3.18. Eisai Co.
    • 12.3.19. Zydus Lifesciences
    • 12.3.20. Aurobindo Pharma
    • 12.3.21. Torrent Pharmaceuticals

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations